Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521048 · ClinicalTrials.gov registry record · Phase 1
Doxycycline in Cutaneous Schwannoma (NF2)
A Phase 1 study of Neurofibromatosis Type 2, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT05521048 is a Phase 1 study of Neurofibromatosis Type 2 that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05521048, a Phase 1 study of Neurofibromatosis Type 2, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.
Conditions Studied
Interventions
- DRUG Doxycycline Injection [Doxy]
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521048
The ClinicalTrials.gov registry entry for NCT05521048 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Doxycycline Injection [Doxy] is the first listed.
NCT05521048 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05521048 about?
NCT05521048 is a clinical study titled "Doxycycline in Cutaneous Schwannoma (NF2)". In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associate...
What is the current status of trial NCT05521048?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-09-19. Estimated completion is 2026-12.
What conditions does trial NCT05521048 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 2.
What interventions are being tested in trial NCT05521048?
The interventions under investigation include: Doxycycline Injection [Doxy] (DRUG).
Who is sponsoring clinical trial NCT05521048?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05521048 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.